Albireo Appoints Ron Cooper CEO
This article was originally published in Scrip
Albireo Limited, a privately held company focused on the development of bile acid modulators to treat orphan pediatric and adult liver diseases, NASH, and gastrointestinal disorders, has named Ron Cooper president and CEO. Cooper is a global biopharmaceutical leader with a track record of growing businesses, brands and organizations in the US and Europe. He joins Albireo from Bristol-Myers Squibb (BMS), where he was president of Europe. During his more than 25 years at BMS, Cooper worked in five different countries and held positions of increasing responsibility in sales, marketing and general management.